Cargando…

Impact of lipid disorders on mortality among Saudi patients with heart failure

BACKGROUND: Dyslipidemia, a known cardiovascular risk factor, is extremely common among Saudis, both adults and children. The impact, however, of dyslipidemia and several other lipid disorders in patients with congestive heart failure in this particular population has not been documented. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Qahtani, M., Al Backer, T., Al Anazi, T., Al Johani, N., Binsalih, S., AlGobain, M., Alshammari, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392377/
https://www.ncbi.nlm.nih.gov/pubmed/25870502
http://dx.doi.org/10.1016/j.jsha.2014.12.003
_version_ 1782365970419941376
author Al Qahtani, M.
Al Backer, T.
Al Anazi, T.
Al Johani, N.
Binsalih, S.
AlGobain, M.
Alshammari, H.
author_facet Al Qahtani, M.
Al Backer, T.
Al Anazi, T.
Al Johani, N.
Binsalih, S.
AlGobain, M.
Alshammari, H.
author_sort Al Qahtani, M.
collection PubMed
description BACKGROUND: Dyslipidemia, a known cardiovascular risk factor, is extremely common among Saudis, both adults and children. The impact, however, of dyslipidemia and several other lipid disorders in patients with congestive heart failure in this particular population has not been documented. This study aims to fill the gap. METHODS: This retrospective, single center study was conducted at King Abdulaziz Medical City, Riyadh, Saudi Arabia. Of the 500 cases seen during the period between 2002 and 2008, 392 were included in the study. Charts were reviewed and information on medical history, medications, and lipid status were documented. RESULTS: Low HDL-cholesterol level was the most common lipid disorder with 82.9%, followed by hypertriglyceridemia (35.2%), atherogenic dyslipidemia (27.8%), and hypercholesterolemia (9.2%). Diabetes mellitus was the single most significant predictor of mortality (p = 0.001). Among the lipid disorders, only low levels of HDL-cholesterol contributed to significant mortality risk [OR 1.29 (Confidence Interval 1.04–1.59) (p-value < 0.01)] adjusted for age, gender and statin use. CONCLUSION: The results of this study suggest that emphasis should be on the elevation of HDL-cholesterol levels among subjects with congestive heart failure, without compromising any ongoing management of LDL-lowering drugs. Management should not be limited to conventional statin use and should promote other treatments to elevate HDL-cholesterol levels.
format Online
Article
Text
id pubmed-4392377
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-43923772015-04-13 Impact of lipid disorders on mortality among Saudi patients with heart failure Al Qahtani, M. Al Backer, T. Al Anazi, T. Al Johani, N. Binsalih, S. AlGobain, M. Alshammari, H. J Saudi Heart Assoc Full Length Article BACKGROUND: Dyslipidemia, a known cardiovascular risk factor, is extremely common among Saudis, both adults and children. The impact, however, of dyslipidemia and several other lipid disorders in patients with congestive heart failure in this particular population has not been documented. This study aims to fill the gap. METHODS: This retrospective, single center study was conducted at King Abdulaziz Medical City, Riyadh, Saudi Arabia. Of the 500 cases seen during the period between 2002 and 2008, 392 were included in the study. Charts were reviewed and information on medical history, medications, and lipid status were documented. RESULTS: Low HDL-cholesterol level was the most common lipid disorder with 82.9%, followed by hypertriglyceridemia (35.2%), atherogenic dyslipidemia (27.8%), and hypercholesterolemia (9.2%). Diabetes mellitus was the single most significant predictor of mortality (p = 0.001). Among the lipid disorders, only low levels of HDL-cholesterol contributed to significant mortality risk [OR 1.29 (Confidence Interval 1.04–1.59) (p-value < 0.01)] adjusted for age, gender and statin use. CONCLUSION: The results of this study suggest that emphasis should be on the elevation of HDL-cholesterol levels among subjects with congestive heart failure, without compromising any ongoing management of LDL-lowering drugs. Management should not be limited to conventional statin use and should promote other treatments to elevate HDL-cholesterol levels. Elsevier 2015-04 2014-12-23 /pmc/articles/PMC4392377/ /pubmed/25870502 http://dx.doi.org/10.1016/j.jsha.2014.12.003 Text en © 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Full Length Article
Al Qahtani, M.
Al Backer, T.
Al Anazi, T.
Al Johani, N.
Binsalih, S.
AlGobain, M.
Alshammari, H.
Impact of lipid disorders on mortality among Saudi patients with heart failure
title Impact of lipid disorders on mortality among Saudi patients with heart failure
title_full Impact of lipid disorders on mortality among Saudi patients with heart failure
title_fullStr Impact of lipid disorders on mortality among Saudi patients with heart failure
title_full_unstemmed Impact of lipid disorders on mortality among Saudi patients with heart failure
title_short Impact of lipid disorders on mortality among Saudi patients with heart failure
title_sort impact of lipid disorders on mortality among saudi patients with heart failure
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392377/
https://www.ncbi.nlm.nih.gov/pubmed/25870502
http://dx.doi.org/10.1016/j.jsha.2014.12.003
work_keys_str_mv AT alqahtanim impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure
AT albackert impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure
AT alanazit impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure
AT aljohanin impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure
AT binsalihs impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure
AT algobainm impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure
AT alshammarih impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure